Pfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatments portfolio, as the drugmaker braces for a steep fall in COVID-19 product sales and loss of exclusivity for some top sellers.
Tag Archive for: targeted therapy
Seagen and LAVA Therapeutics inked a licensing deal for LAVA’s Gammabody platform for solid tumors, which can potentially exceed $700 million.
